Figure 5. Validation of FAM83A conferring resistance to EGFR inhibitor.

A. Vector control or FAM83A overexpressing T4-2 cells were plated in 3D lrECM with reverting compound, EGFR-TKI AG1478. B. IC₅₀ of lapatinib for vector control or FAM83 overexpression SKBR3 cells. C. Drug response to lapatinib or gefitinib in vector control or FAM83A overexpressing T4-2 cells in 3D lrECM culture. D. Tumor growth derived from vector or FAM83A–overexpression T4-2 cells xenografted in nude mice. (C) and (D) were adapted from Figures 3 and 4 in Lee et al. (2012) . Scale bars in A, C = 50 μm.